Clinical Trials for ATIR

ATIR (Allodepleted T-cell Immunotherapeutics) is no longer being developed by Kiadis. Consequently, the Phase 3 (CR-AIR-009) HATCY [NCT02999854] study has been terminated.

 

Kiadis announced on November 12th, 2019 that it was terminating development the ATIR101 platform and would instead be aligning corporate resources to fully support the Kiadis natural killer-cell (K-NK) platform.

Upcoming Trials

If you are a medical professional and would like information about becoming an investigator for one of our clinical trials, please contact

clinicaltrials@kiadis.com